DK586784A - Thiazid-blandet anion/kationkompleks - Google Patents

Thiazid-blandet anion/kationkompleks Download PDF

Info

Publication number
DK586784A
DK586784A DK586784A DK586784A DK586784A DK 586784 A DK586784 A DK 586784A DK 586784 A DK586784 A DK 586784A DK 586784 A DK586784 A DK 586784A DK 586784 A DK586784 A DK 586784A
Authority
DK
Denmark
Prior art keywords
thiazide
salts
achieve
thiazides
administration
Prior art date
Application number
DK586784A
Other languages
Danish (da)
English (en)
Other versions
DK586784D0 (da
Inventor
Ronald B Miller
Stewart Thomas Leslie
Peter Hofer
Alfred Halpern
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24234891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK586784(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of DK586784D0 publication Critical patent/DK586784D0/da
Publication of DK586784A publication Critical patent/DK586784A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK586784A 1983-12-09 1984-12-07 Thiazid-blandet anion/kationkompleks DK586784A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/559,755 US4898729A (en) 1983-12-09 1983-12-09 Treatment of hypertension, compounds and compositions for antihypertension and diuresis

Publications (2)

Publication Number Publication Date
DK586784D0 DK586784D0 (da) 1984-12-07
DK586784A true DK586784A (da) 1985-06-10

Family

ID=24234891

Family Applications (1)

Application Number Title Priority Date Filing Date
DK586784A DK586784A (da) 1983-12-09 1984-12-07 Thiazid-blandet anion/kationkompleks

Country Status (17)

Country Link
US (1) US4898729A (fr)
EP (1) EP0154009B1 (fr)
JP (4) JPS60139620A (fr)
AT (1) ATE91416T1 (fr)
AU (2) AU564078B2 (fr)
CA (1) CA1279575C (fr)
DE (1) DE3486177T2 (fr)
DK (1) DK586784A (fr)
FI (1) FI844593L (fr)
GR (1) GR81209B (fr)
IE (1) IE60713B1 (fr)
IL (1) IL73422A0 (fr)
IN (1) IN162797B (fr)
MX (1) MX156438A (fr)
NZ (1) NZ210056A (fr)
PT (1) PT79604B (fr)
ZA (1) ZA848619B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006464A1 (fr) * 1986-05-02 1987-11-05 Gaf Corporation Complexes hydrosolubles medicamenteux a base de lactame polyvinylique
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
US5132296A (en) * 1987-08-14 1992-07-21 Cherksey Bruce D Membrane NA+ channel protein and related therapeutic compounds
EP0418597A3 (en) * 1989-09-21 1991-11-27 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
DE60017888T2 (de) * 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
PT2060259E (pt) 2001-11-01 2010-04-26 Spectrum Pharmaceuticals Inc Composições médicas para o tratamento intravesical do cancro da bexiga
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
WO2007092963A1 (fr) * 2006-02-09 2007-08-16 Spectrum Pharmaceuticals, Inc. Traitement du cancer de la vessie et procedes correspondants
KR101368997B1 (ko) * 2009-10-20 2014-03-03 재단법인 의약바이오컨버젼스연구단 벤즈티아지드를 유효성분으로 함유하는 항암용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL247297A (fr) * 1959-01-14
US3781430A (en) * 1962-10-30 1973-12-25 Merck & Co Inc Diuretic formulations
FR3608M (fr) * 1964-02-03 1965-10-11 Merck & Co Inc Compositions diurétiques.
NL7508856A (nl) * 1974-08-16 1976-02-18 Merck & Co Inc Werkwijze voor het bereiden van preparaten tegen hypertensie.
FR2314719A1 (fr) * 1975-04-11 1977-01-14 Roussel Uclaf Nouveau medicament notamment diuretique
GB1525296A (en) * 1975-08-04 1978-09-20 Geistlich Soehne Ag Antibacterial compositions
DE2546577B2 (de) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
GB1509778A (en) * 1975-10-29 1978-05-04 Leo Pharm Prod Ltd Pharmaceutical composition and dosage units thereof
DE2638716A1 (de) * 1976-08-27 1978-03-02 Ici Gmbh Antihypertensiva
CA1120400A (fr) * 1977-12-27 1982-03-23 Zola P. Horovitz Traitement de l'hypertension et medicaments utilises a cette fin
CH639273A5 (de) * 1978-09-12 1983-11-15 Hoffmann La Roche Diuretische mittel.
DE3027392A1 (de) * 1980-07-17 1982-02-04 Schering Ag, 1000 Berlin Und 4619 Bergkamen Synergistische kombination eines (beta) -rezeptorenblockers mit einem saluretikum
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
JPS5788117A (en) * 1980-11-21 1982-06-01 Smithkline Corp Gelatin capsule containing triamterene
JPS5933213A (ja) * 1982-07-27 1984-02-23 ミラン・フア−マスウ−テイカルズ・インコ−ポレイテイド 医薬組成物及びその製造方法
JPS5927812A (ja) * 1982-08-05 1984-02-14 Kotobuki Seiyaku Kk ニフエジピン製剤の製造方法
JPS5982314A (ja) * 1982-10-29 1984-05-12 インステイテユト・オルガニチエスコゴ・シンテザ・アカデミイ・ナウク・ラトビイスコイ・エスエスア−ル 抗菌性医薬組成物

Also Published As

Publication number Publication date
IE843148L (en) 1985-06-09
ATE91416T1 (de) 1993-07-15
MX156438A (es) 1988-08-22
CA1279575C (fr) 1991-01-29
GR81209B (en) 1985-04-10
ZA848619B (en) 1985-06-26
AU3641484A (en) 1985-06-13
EP0154009B1 (fr) 1993-07-14
JPH09278655A (ja) 1997-10-28
US4898729A (en) 1990-02-06
AU602899B2 (en) 1990-11-01
IN162797B (fr) 1988-07-09
JPH10152441A (ja) 1998-06-09
IE60713B1 (en) 1994-08-10
AU7440287A (en) 1987-10-08
AU564078B2 (en) 1987-07-30
DK586784D0 (da) 1984-12-07
JPS60139620A (ja) 1985-07-24
PT79604A (en) 1985-01-01
EP0154009A1 (fr) 1985-09-11
PT79604B (en) 1986-11-18
FI844593L (fi) 1985-06-10
JPH08253418A (ja) 1996-10-01
FI844593A0 (fi) 1984-11-22
DE3486177D1 (de) 1993-08-19
DE3486177T2 (de) 1994-03-10
NZ210056A (en) 1989-01-06
IL73422A0 (en) 1985-02-28

Similar Documents

Publication Publication Date Title
DK586784A (da) Thiazid-blandet anion/kationkompleks
DE69432027T2 (de) Verwendung von schilddrüsenhormone in ein medizinisches behandlungsverfahren
GEP19970823B (en) Composition for coating of tooth solid tissues
NZ334537A (en) Two phase remineralising composition comprising a source of calcium ions and a source of phosphate ions with a water soluble polyphosphate salt
FI831314A0 (fi) Kompositioner som befraemjar munhygien
EP0210590A3 (fr) Additifs polymères pour l'eau
ES468510A1 (es) Un procedimiento para la preparacion de interfenilen-8-aza-9-dioxotia-11,12-seco-prostaglandinas
WO1992013813A3 (fr) Compositions pour engrais sous forme de composes solides a solubilite accrue
PH25088A (en) Anticalculus oral compositions
DE3781368T2 (de) Granulierte trikalziumphosphat-zusammensetzungen, geeignet zur tablettierung durch direkte kompression.
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
GB1511196A (en) Creatinine pyrolidonecarboxylate
GB1262949A (en) Indenopyridine derivatives
GB1450524A (en) 2,4,6-triiodo-5-methoxyacetamido-n-methylisophthalamic acid and salts acyl halides and esters thereof
ES2104334T3 (es) Recuperacion de eritorbatos de soluciones fotograficas.
GB1327115A (en) Detergent compositions
DE3564423D1 (en) Purification of 4-fluoro-4'-hydroxy-benzophenone
Givant Putting Pudong in perspective.
FR2342726A1 (fr) Nouvelles compositions diuretiques
GB1234685A (en) Preparation of pyruvaldehyde
Daelemans et al. Calcium Carbonate as Phosphate Binder in Patients on Low-Calcium Dialysate
Ishida et al. Effects of So 42- and HCO 3- Upon the Artificial Waters Capable of Generating Pits on Aluminum
ES8702477A1 (es) Procedimiento para producir quemiluminiscencia
FR2414048A1 (fr) Benzofuro (2,3-c) pyridines, leur procede de preparation et leur application en therapeutique
JPS52119657A (en) Method for preventing degrading of cationic high polymers of mannich type

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment